去氨加压素可作为逆转重型颅脑创伤患者血小板功能障碍的节约输血选择
这项回顾性研究纳入2015年7月至2016年10月某城市一级创伤中心收治的57例钝性创伤合并重型颅脑创伤(头部简明损伤定级≥3)且血栓弹力图提示二磷酸腺苷抑制≥60%的患者,按初始治疗分为去氨加压素组(n=23)和血小板输注组(n=34)。去氨加压素组损伤严重度评分更高(29 vs 23,p=0.045),但两组头部简明损伤定级、入院血小板计数及其他凝血指标无差异。治疗前两组二磷酸腺苷抑制率相似(86% vs 89%,p=0.34),治疗后两组对二磷酸腺苷抑制的纠正程度无差异(p=0.28)。作者认为去氨加压素可能作为血小板输注的替代方案用于纠正此类患者的血小板功能障碍。
要点
- 研究纳入头部简明损伤定级≥3且血栓弹力图二磷酸腺苷抑制≥60%的钝性创伤患者,去氨加压素组23例、血小板输注组34例。
- 去氨加压素组损伤严重度评分高于血小板输注组(29 vs 23,p=0.045),但两组头部简明损伤定级无差异(4 vs 4,p=0.16)。
- 治疗前两组二磷酸腺苷抑制率相似(86% vs 89%,p=0.34),治疗后两组纠正程度无差异(p=0.28)。
- 作者结论:在重型颅脑创伤合并血小板功能障碍患者中,去氨加压素可能作为血小板输注的替代方案。
适用人群与场景
- 2015年7月至2016年10月入住某城市一级创伤中心的钝性创伤患者,合并重型颅脑创伤(头部简明损伤定级≥3)且血栓弹力图提示血小板功能障碍(二磷酸腺苷抑制≥60%),并接受了治疗。
诊断标准与关键阈值
- 重型颅脑创伤定义为头部简明损伤定级≥3。
- 血小板功能障碍定义为血栓弹力图二磷酸腺苷抑制≥60%。
处置流程与药物剂量
- 按本研究中心惯例,重型颅脑创伤合并血小板功能障碍患者输注1单位单采血小板以逆转抑制。
- 血小板短缺期间,以去氨加压素替换初始治疗。
研究设计与关键结果
- 回顾性研究,共纳入57例患者,去氨加压素组23例、血小板输注组34例。
- 去氨加压素组损伤严重度评分高于血小板输注组(29 vs 23,p=0.045),两组头部简明损伤定级无差异(4 vs 4,p=0.16)。
- 两组入院血小板计数无差异(244 ± 68 × 10/μL vs 265 ± 66 × 10/μL,p=0.24),凝血酶原时间、部分凝血活酶时间、国际标准化比值等其他凝血参数亦无差异。
- 治疗前两组血栓弹力图二磷酸腺苷抑制率相似(86% vs 89%,p=0.34)。
- 治疗后去氨加压素组与血小板输注组对二磷酸腺苷抑制的纠正程度无差异(p=0.28)。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:治疗性,level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在重型颅脑创伤合并血小板功能障碍患者中,去氨加压素可能作为血小板输注的替代方案来纠正血小板功能障碍。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Platelet dysfunction (PD) is an independent predictor of mortality in patients with severe traumatic brain injury (sTBI). Platelet transfusions (PLTs) have been shown to be an effective treatment strategy to reverse platelet inhibition. Their use is contingent on availability and may be associated with increased cost and transfusion-related complications, making desmopressin (DDAVP) attractive. We hypothesized that DDAVP would correct PD similarly to PLTs in patients with sTBI.
METHODS: This retrospective study evaluated all blunt trauma patients admitted to an urban, level 1 trauma center from July 2015 to October 2016 with sTBI (defined as head abbreviated injury scale [AIS] ≥3) and PD (defined as adenosine diphosphate [ADP] inhibition ≥60% on thromboelastography) and subsequently received treatment. Per our institutional practice, patients with sTBI and PD are transfused one unit of apheresis platelets to reverse inhibition. During a platelet shortage, we interchanged DDAVP for the initial treatment. Patients were classified as receiving DDAVP or PLT based on the initial treatment.
RESULTS: A total of 57 patients were included (DDAVP, n = 23; PLT, n = 34). Patients who received DDAVP were more severely injured (injury severity score, 29 vs. 23; p = 0.045), but there was no difference in head AIS (4 vs. 4, p = 0.16). There was no difference between the two groups in admission platelet count (244 ± 68 × 10/μL vs. 265 ± 66 × 10/μL, p = 0.24) or other coagulation parameters such as prothrombin time, partial thromboplastin time, or international normalized ratio. Before treatment, both groups had similar ADP inhibition as measured by thromboelastography (ADP, 86% vs. 89%, p = 0.34). After treatment, both the DDAVP and PLT groups had similar correction of platelet ADP inhibition (p = 0.28).
CONCLUSION: In patients with severe traumatic brain injury and PD, DDAVP may be an alternative to PLTs to correct PD.
LEVEL OF EVIDENCE: Therapeutic, level IV.
参考来源
- Furay EJ, Daley MJ, Satarasinghe P, et al. Desmopressin is a transfusion sparing option to reverse platelet dysfunction in patients with severe traumatic brain injury. J Trauma Acute Care Surg. 2020. PMID: 31688782. doi:10.1097/TA.0000000000002521
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。